Paragate Medical and the EIC Accelerator: Draining Heart Failure
Paragate Medical, founded in 2016 by interventional cardiologist Dr. Yair Feld and registered in Nazareth, Israel, is developing an implantable peritoneal ultrafiltration device that continuously draws excess fluid and salt from the body of heart failure patients across the lining of the abdomen and sends it to the bladder to be passed as urine. It was selected in the EIC Accelerator's January 2023 cut-off for blended finance and was awarded an EU grant contribution of €2.50 million for FILBERT, a €3.99 million project that ran from August 2023 to July 2025, according to CORDIS.
The project is closed. Its final report states that Paragate produced a "Gen 1.5" system for an 8-patient trial, validated it in the lab and in animals, obtained ethics and regulatory approvals, activated four trial sites in Europe and "launched the CLEAR-HF clinical trial as a pilot study", according to the CORDIS reporting page. The fully implantable second-generation pump was "ready to proceed to the next testing phase for subsequent design freeze". CLEAR-HF is registered on ClinicalTrials.gov as NCT06689553: it started on 28 September 2025, enrolled 2 patients and was terminated on 5 May 2026. The registry states the sponsor ended it "due to financial restrictions" and that the decision was administrative and commercial, not related to safety. No results are posted.
Company file
- Legal entity
- Paragate Medical Ltd, Nazareth, Israel
- Founder
- Dr. Yair Feld
- Device
- IPUD (Implantable Peritoneal Ultrafiltration Device)
- Trial
- CLEAR-HF, Serbia and Spain, terminated May 2026
- Earlier pilot
- ACWR-HF, 3 patients enrolled, 2022 to 2024, terminated
- Earlier EU grant
- €50,000, Horizon 2020 SME Instrument, 2018
- Earlier EIC project
- IPUD, EIC SME Instrument Phase 2 (Horizon 2020), 1 Aug 2019 to 31 Jul 2022, €2.04M grant
- Website
- About page showing a software error, September 2026
- EIC funding
- Blended finance; €2.50M grant
Where Paragate Stands Now
In December 2025 Feld presented early data from CLEAR-HF at the CSI Focus D-HF meeting in Frankfurt, showing that the second patient, implanted on 5 November 2025, drained roughly 600 to 900 ml of fluid a day with sodium levels between those of blood and urine, according to an account by Sharing from Israel. The trial planned up to 8 patients in Serbia and Spain with six months of follow-up each, but the registry record, last updated in May 2026, lists 2 enrolled and the trial as terminated by the sponsor for financial reasons. When checked in September 2026, the About page of the company's website returned a WordPress "critical error".
The record
From an EU feasibility grant to a stopped pilot trial
Paragate launched the CLEAR-HF pilot during the EIC project and implanted its patients after it ended. The registry lists 2 enrolled and the trial terminated by the sponsor for financial reasons in May 2026. The next-generation device is still being designed.
- 2016Paragate foundedBy cardiologist Dr. Yair Feld
- Aug 2018Horizon 2020 SME grant€50,000 feasibility study
- Aug 2019EIC SME Instrument Phase 2IPUD: miniaturisation and platform upgrade€2.04M grant
- Feb 2022ACWR-HF pilot starts3 patients enrolled; terminated Jan 2024 over recruitment
- Jan 2023EIC Accelerator cut-offFILBERTblended finance
- Aug 2023Project starts€2.50M EU grant
- Jul 2025Project endsCLEAR-HF launched; 4 European sites active
- Nov 2025Second patient implantedActivated 21 November
- Dec 2025Early data presented600-900 ml drained per day
- May 2026CLEAR-HF terminatedSponsor cites financial restrictions, not safety
CORDIS, ClinicalTrials.gov (NCT05140759, NCT06689553) and Sharing from Israel, reporting a D-HF conference presentation.
"FILBERT has the unique opportunity to strengthen Europe's sovereignty within the CHF industry, as Paragate may become the leading global provider of outpatient fluid-overload prevention therapy."
Paragate Medical, final report to the EICThe Technology: A Bypass for the Kidneys
Patients with advanced heart failure retain fluid in their lungs and limbs. The standard treatment is diuretic drugs, and the final report states that about 30% of patients become resistant to them and must keep returning to hospital. Paragate's device collects fluid in a membrane-covered chamber in the abdomen that lets water and salt through but not proteins, and pumps it slowly to the bladder. Doctors are meant to adjust it remotely, and patients recharge it wirelessly.
The pilot trial
CLEAR-HF: planned and enrolled patients
CLEAR-HF planned up to 8 patients in Serbia and Spain with 6-month follow-up. The registry lists 2 enrolled and the trial terminated on 5 May 2026 for financial reasons, which it says were unrelated to safety. No results are posted.
CORDIS final report and ClinicalTrials.gov, NCT06689553.
What the EIC Award Promised, and What the Record Shows
FILBERT was not Paragate's first large EU grant for the device. At the 3 April 2019 cut-off of the EIC SME Instrument Phase 2, part of the Horizon 2020 EIC pilot, the company was selected for IPUD, which ran from 1 August 2019 to 31 July 2022 with an EU contribution of €2,036,849.50 towards a total cost of €2,957,025.48, to miniaturise the implant, upgrade its management platform and validate it in a pilot clinical trial. The final report says the team worked on miniaturising the system and upgraded the platform, but verification, validation and animal testing were still under way and ethics approval for the trial was still being prepared. Separately, Paragate registered an earlier pilot, ACWR-HF, which started on 24 February 2022 at sites in Georgia, Israel and Poland, enrolled 3 patients and was terminated in January 2024 because of "challenges in recruitment". No results are posted. The CLEAR-HF pilot was prepared under FILBERT, whose report lists the lab and animal validation and the approvals as completed.
The award promised an implantable device and management platform to prevent chronic fluid congestion. During the project Paragate prepared and launched the CLEAR-HF pilot with its interim device. The first CLEAR-HF implants and data came after the project ended, the trial stopped after two patients, and the fully implantable second-generation device had not reached design freeze.
- Trial approvals and sitesDelivered4 European sites active.
- CLEAR-HF pilotPartial2 of 8 enrolled; stopped.
- Fully implantable Gen 2PartialBefore design freeze.
- Fewer hospital staysUnverifiedNo results posted.
The Money
The EU contribution covers 63% of the project's total cost. Paragate also received €50,000 from the EU in 2018 for a feasibility study of the same device, according to CORDIS. Its private funding, revenue and losses are not public, and whether the EIC Fund invested under the blended finance award has not been disclosed.
The EU money
EU grants to Paragate Medical
Paragate has received three EU grants: a small feasibility award in 2018, an EIC SME Instrument Phase 2 grant in 2019 and the EIC Accelerator grant in 2023.
CORDIS, projects 827951, 874316 and 190134274. Values in € thousands.
The project budget
How the €3.99M project cost splits
The EU contribution covers 63% of the FILBERT project's total cost. CORDIS does not show who funded the rest.
CORDIS, project 190134274. Values in € millions.
What Cannot Be Checked
Questions for the EIC
Whether the EIC Fund invested, what safety and efficacy data the two CLEAR-HF patients produced, and how Paragate plans to finance further development are not public. Neither registered pilot has posted results.
Why Europe Should Care
The final report calls heart failure congestion the largest healthcare cost generator in Europe and the US. A device that keeps patients out of hospital would matter. The EU has funded an Israeli company to test it in Serbian and Spanish hospitals; the trial ended after two patients and no results are posted.
What the award promised
An implant and remote platform to prevent chronic fluid congestion in heart failure.
What the record shows
A pilot trial stopped by the sponsor for financial reasons after two patients, early drainage data, and an unfinished second-generation device.
The Verdict
A pilot cut short
Paragate used EIC money to prepare and launch the CLEAR-HF pilot, a hard milestone for any implant. The trial stopped after two patients for financial reasons that the registry says were unrelated to safety. Whether the device works, and whether the company can finance the next step, remains open.
Paragate Medical and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
Sources
- CORDIS, FILBERT fact sheet
- CORDIS, FILBERT final report
- CORDIS, IPUD feasibility project, 2018
- CORDIS, IPUD fact sheet, 2019 to 2022 and final report
- European Commission, EIC SME Instrument Phase 2 selected companies, 3 April 2019 cut-off
- ClinicalTrials.gov, CLEAR-HF (NCT06689553) and ACWR-HF (NCT05140759)
- Sharing from Israel, Paragate's first-in-human data
Industry
HealthMedical devices
- Focus
- Cardiovascular devices
- Technologies
- Implantable devices
- Membranes
- Keywords
- Heart failure
- Fluid overload
- Diuretic resistance
- Ultrafiltration